
CME Posttest

THERAPEUTIC DECISIONS IN THE CARE OF HIGH-RISK ANTIFUNGAL PATIENTS: A CASE-BASED APPROACH *Combination Antifungal Therapy: When and Why?*

Release Date: December 1, 2006

CME Instructions

To receive documentation of your participation in this CME activity for a total of 1 hour of CME credit, please complete the following steps:

1. Read the newsletter carefully.
2. Complete the CME Posttest included in this newsletter.
3. Mail your CME Posttest to:

Liz Alter
The MedEd Group, LLC
56 Clarken Drive
West Orange, New Jersey 07052
Fax: 973-847-5624
4. After reading the newsletter, complete the CE Evaluation Survey and mail or fax it to the above.
5. This posttest and the evaluation survey must be received by December 1, 2007 for you to be eligible to receive CE credit.

NAME

SPECIALTY

STREET ADDRESS

CITY

STATE

ZIP

PHONE NUMBER

FAX NUMBER

EMAIL

Posttest Questions

1. In HSCT patients, the most common cause of IFIs in the post-engraftment period is:
 - a. *Candida* spp.
 - b. *Aspergillus* spp.
 - c. Zygomycetes
 - d. *Fusarium*
2. In the Phase III trial that evaluated the use of voriconazole monotherapy for invasive aspergillosis, what was the response rate in allogeneic HSCT recipients?
 - a. 58%
 - b. 44%
 - c. 32%
 - d. 26%
3. Risk factors for zygomycosis include all of the following except:
 - a. GVHD
 - b. Diabetes
 - c. Voriconazole prophylaxis
 - d. Osteoarthritis
4. Which of the following combinations have the potential for antagonism, given that they act at the same site to exert their antifungal activity?
 - a. amphotericin B and flucytosine
 - b. itraconazole and amphotericin B
 - c. voriconazole and caspofungin
 - d. all of the above
5. Which of the following statements is FALSE concerning studies of antifungal combinations?
 - a. The use of combination therapy for invasive mold infections has been well-established in large clinical trials
 - b. Preclinical animal studies have shown that caspofungin plus ABLC is more effective than ABLC alone for Zygomycetes
 - c. Trials have established the efficacy of amphotericin B plus flucytosine for the treatment of cryptococcal meningitis in the AIDS population
 - d. Amphotericin B plus fluconazole has been shown to be more effective than fluconazole alone for treatment of candidemia in non-neutropenic patients

EVALUATION FORM

THERAPEUTIC DECISIONS IN THE CARE OF HIGH-RISK ANTIFUNGAL PATIENTS: A CASE-BASED APPROACH *Combination Antifungal Therapy: When and Why?*

Release Date: December 1, 2006

EVALUATION FORM – PLEASE PRINT CLEARLY

The School of Pharmacy of the University of North Carolina respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form. Please note that a CE Credit Form is issued only upon receipt of your completed evaluation form and posttest.

PLEASE ANSWER THE FOLLOWING QUESTIONS BY CIRCLING THE APPROPRIATE RATING:

5 = Outstanding

4 = Good

3 = Satisfactory

2 = Fair

1 = Poor

EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES

Upon completion of this activity, participants should be able to:

- | | | | | | |
|---|---|---|---|---|---|
| • Review the prevalence and changing resistance patterns of mycoses in high-risk hematology/oncology patients | 5 | 4 | 3 | 2 | 1 |
| • Discuss the rationale for early versus late initiation of empiric antifungal therapy | 5 | 4 | 3 | 2 | 1 |
| • Evaluate the latest findings on the use of antifungal agents for empiric therapy in neutropenic patients | 5 | 4 | 3 | 2 | 1 |
| • Describe the differences among lipid amphotericin agents for antifungal management of high-risk patients | 5 | 4 | 3 | 2 | 1 |

Please describe some specifics of what you learned as a result of this activity.

OVERALL EFFECTIVENESS OF THE ACTIVITY

- | | | | | | |
|---|---|---|---|---|---|
| Objectives were related to overall purpose/goal(s) of activity | 5 | 4 | 3 | 2 | 1 |
| Related to my practice needs | 5 | 4 | 3 | 2 | 1 |
| Will influence how I practice | 5 | 4 | 3 | 2 | 1 |
| Will help me improve patient care | 5 | 4 | 3 | 2 | 1 |
| Stimulated my intellectual curiosity | 5 | 4 | 3 | 2 | 1 |
| Overall, the activity met my expectations | 5 | 4 | 3 | 2 | 1 |
| Presentation was educational and not for the purpose of promoting any commercial product or service | 5 | 4 | 3 | 2 | 1 |

Will the information presented cause you to make any changes in your practice? ___ Yes ___ No

If yes, please describe any change(s) you plan to make in your practice as a result of this activity.

How committed are you to making these changes? 5 (Very committed) 4 3 2 1 (Not at all committed)

Additional comments about this activity?

Do you feel future activities on this subject matter are necessary and/or important to your practice? _____ Yes _____ No

EVALUATION FORM
THERAPEUTIC DECISIONS IN THE CARE OF HIGH-RISK ANTIFUNGAL PATIENTS:
A CASE-BASED APPROACH *Combination Antifungal Therapy: When and Why?*

Please list any other topics that would be of interest to you for future educational activities:

The program was educationally unbiased and not promotional: ____ Yes ____ No

If no, please explain: _____

Specialty: Infectious Diseases Hematology Oncology Bone Marrow Transplant Solid Organ Transplant

Degree: MD DO PharmD RPh NP RN BS PA Other _____

IF YOU WISH TO RECEIVE CREDIT FOR THIS ACTIVITY, PLEASE FILL IN YOUR NAME AND ADDRESS AND MAIL ALONG WITH YOUR POSTTEST TO:

Release Date: December 1, 2006

Liz Alter
The MedEd Group, LLC
56 Clarken Drive
West Orange, New Jersey 07052
Fax: 973-847-5624

I certify my actual time spent to complete this educational activity to be ____ hour(s) [not to exceed 1.0 hours].

Signature _____

PLEASE PRINT CLEARLY

NAME _____

SPECIALTY _____

STREET ADDRESS _____

CITY _____ STATE _____ ZIP _____

PHONE NUMBER _____ FAX NUMBER _____

EMAIL _____